



**FULBRIGHT & JAWORSKI L.L.P.**

A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701-3271  
WWW.FULBRIGHT.COM


STEVEN L. HIGHLANDER  
PARTNER  
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3184  
TELEPHONE: (512) 477-0801  
FACSIMILE: (512) 536-4799

1640  
RECEIVED  
MAR 27 2003  
TECH CENTER 1600/2900

March 17, 2003

Commissioner for Patents  
Washington, DC 20231

CERTIFICATE OF MAILING 37 C.F.R. § 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date below:	
March 17, 2003 Date	 Steven L. Highlander


RE: *U.S. Patent Application No. 09/852,587 entitled "PREVENTION OF INSULIN-DEPENDENT DIABETES, COMPLICATIONS THEREOF, OR ALLOGRAFT REJECTION BY INHIBITION OF CYCLOOXYGENASE-2 ACTIVITY" – Tahereh Tabatabaie and Yashige Kotake*  
*Our reference: OMRF:008US*  
*Client reference: 2000-004-002*

Sir:

Enclosed please find a Revocation and Substitute Power of Attorney on the above-reference matter and a return postcard to acknowledge receipt of this document. Please date stamp and mail this postcard.

It is believed that no fee is due with this communication, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed document, the Commissioner is authorized to deduct or credit the appropriate fees from or to Fulbright & Jaworski Deposit Account No. 50-1212/OMRF:008US.

Respectfully submitted,



Steven L. Highlander

SLH/mar  
Encl: as noted

**BEST AVAILABLE COPY**

25274309.1